The swine flu is a severe contagious disease caused
by H1N1 virus which leads to respiratory tract infection,
other complications such as bronchitis and pneumonia
in human. World Health Organization reported 12 787
cumulative confirmed cases and 413 cumulative deaths
cases, all caused by H1N1, on 18 Oct 2009[13]. H1N1
contains two surface glycoproteins: hemagglutinin
and neuraminidase. Hemagglutinin facilitates the
influenza virus to attach to a host cell during the initial
infection and viral RNA enters the cell by endocytosis.
Neuraminidase cleaves α-ketosidic linkage between
the sialic acid (N-acetylneuraminic) and an adjacent
sugar residue and spread infection in cells. The amino
acid sequence of neuraminidase is coded by the 6th RNA
segment and the polypeptide chain and neuraminidase
comprises of 470 amino acid residues. The inhibition of
neuraminidase is useful in prevention of H1N1 and could
serve as potential drug target. Due to development of
resistance in many strains of H1N1, the Food and Drug
administration approved neuraminidase inhibitor drugs
such as Oseltamivir and Zanamivir[14-16]. Moreover, due
to several sides effects like nausea, vomiting, abdominal
pain and headache, rash and sometimes allergic reactions
including anaphylaxis etc, there is a call for new
inhibitors against H1N1 influenza A virus with less or no
side effects.